Growing Midwestern Clinical Research Organization Selects OmniComm Systems to Provide...

Growing Midwestern Clinical Research Organization Selects OmniComm Systems to
Provide eClinical Solutions for Phase IV Studies

FT. LAUDERDALE, Fla., July 30 /PRNewswire-FirstCall/ -- OmniComm Systems, Inc.
(OTC Bulletin Board: OMCM), a leader in integrated electronic data capture
(EDC) solutions for clinical trials announced today that a growing US Clinical
Research Organization (CRO) has selected OmniComm to provide eClinical
solutions in connection with two of the CRO's Phase IV studies covering
approximately 27 sites and more than 700 subjects. Additional details were not
disclosed. Phase IV studies take place after a drug has been approved for
marketing and are designed to provide broader experience in evaluating the
safety and effectiveness of the new medicine in larger numbers of patients,
subpopulations of patients, and to compare and/or combine it with other
available treatments.

"We are pleased to have been selected by this CRO to provide eClinical
solutions for these important Phase IV studies," said Cornelis F. Wit,
OmniComm's President and CEO. "We believe the broad scope of our integrated
eClinical solutions, enhanced by the recent acquisition of eResearch
Technology's data capture unit, positions us well to offer a broad array of
solutions, especially for CRO's, pharmaceutical, biotech and medical device
companies seeking cost-effective tools to capture and track outcomes of
clinical trials conducted at multiple locations. We look forward to expanding
the range of services we provide for companies seeking to increase
efficiencies in their clinical activities."

About OmniComm
OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet
solutions to pharmaceutical, biotechnology, research and medical device
organizations that conduct life changing clinical trial research. OmniComm's
growing base of satisfied customers is a direct result of the company's
commitment to deliver products and services that ensure ease of use, faster
study build, ease of integration and better performance. OmniComm's client
intuitive pricing model allows companies that range from small, to mid-size to
large scale institutions to safely and efficiently capitalize on their
clinical research investments. OmniComm Systems, Inc. has corporate
headquarters in Ft. Lauderdale, Florida and offices in Bonn, Germany, Tula,
Russia, California, Connecticut, Georgia, Illinois, New Jersey, New York,
North Carolina and Tennessee.

Safe Harbor Disclaimer
Statements made by OmniComm included in this release may constitute
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. Such statements involve a number of risks and
uncertainties such as the Company's ability to obtain new contracts and
accurately estimate net revenues due to uncertain regulatory guidance,
variability in size, scope and duration of projects, and internal issues at
the sponsoring client, integration of acquisitions, competitive factors,
technological development, and market demand. As a result, actual results may
differ materially from any financial outlooks stated herein. Further
information on potential factors that could affect the Company's financial
results can be found in the Company's Reports on Form 10-K and 10-Q filed with
the Securities and Exchange Commission. The Company undertakes no obligation
to publicly update any forward-looking statement, whether as a result of new
information, future events, or otherwise.

SOURCE OmniComm Systems, Inc.

Catherine Lemercier of OmniComm Systems, Inc, +1-954-473-1254 Extension 283,
clemercier@omnicomm.com; or Gary Nash, CEOcast, Inc. for OmniComm,
+1-212-732-4300, gnash@ceocast.com; or Stephen Johnson, +1-954-377-1726